Direct Medical Cost Analysis Among Coronary Heart Disease and Heart Failure Outpatients at One Hospital

https://doi.org/10.22146/jmpf.38170

Nunik Dewi Kumalasari(1), Abdul Rahem(2), Bobby Presley(3), Eko Setiawan(4*)

(1) Master of Pharmacy Study Program, Universitas Surabaya, Surabaya
(2) Faculty of Pharmacy, Universitas Airlangga, Surabaya
(3) Faculty of Pharmacy, Universitas Surabaya
(4) Faculty of Pharmacy, Universitas Surabaya
(*) Corresponding Author

Abstract


Long-term treatment of cardiovascular disease may give impact in a high burden of medical cost for the patient. A concern arises whether the health budget allocation prepared by the Indonesian Government through "Jaminan Kesehatan Nasional" program is enough to cover medical cost for the outpatient treatment. This study aims to calculate the direct medical cost of patients with coronary heart disease and heart failure and compare it with the Indonesian Case Base Groups (INA-CBGs) tariff. This is a prospective and observational study carried out in one of the public hospitals in East Java between February and April 2015. All data related to outpatients with coronary heart disease and heart failure were analysed. Direct medical cost analysis in this study calculated from a combination of cost of medication, health professional services, electrocardiography, emergency care services, and laboratory test component, then it was compared with INA-CBGs tariff from ICD 10. Total of 390 patients included were 387 patients with coronary heart disease (99.23%) and three (3) patients with heart failure (0.77%). Average direct medical cost for patients with coronary heart disease and heart failure were IDR 130.593,6 (range IDR 50.282 – IDR 385.911) and IDR 128.587 (range IDR 112.832 – IDR 140.103), respectively. Even though this study showed that budget allocation of INA-CBGs could cover the average direct medical cost of patients with both of diseases, some patients had a direct medical cost higher than the limit of INA-CBGs allocation. Therefore, an optimal interprofessional collaboration between physician and pharmacist needed to provide medical treatment based on patient needs and keep it within budget allocation range.

Keywords


coronary heart disease; heart failure; direct medical cost

Full Text:

PDF


References

  1. Le C, Fang Y, Linxiong W, Shulan Z, Golden AR. Economic burden and cost determinants of coronary heart disease in rural southwest China: a multilevel analysis. Public Health. 2015 Jan;129(1):68-73.
  2. Chang HS, Kim HJ, Nam CM, Lim SJ, Jang YH, Kim S, et al. The socioeconomic burden of coronary heart disease in Korea. J Prev Med Public Health. 2012; 45(5):291–300.
  3. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368-76.
  4. Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23(1):131-145.
  5. Montalescot G, Sechtem U, Achenbach S, Andreoti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2494-3003.
  6. Krum H, Driscoll A. Management of heart failure. Med J Aust. 2013;199(5):334-339.
  7. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al, 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129-2200.
  8. Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):357.e7-357.e27.
  9. Hood SR, Giazzon AJ, Seamon G, Lane KA, Wang J, Eckert GJ, et al. Pharmacotherapy. 2018;38(5):539-545.
  10. 10. Banerjee A, Khandelwal S, Nambiar L, Saxena M, Peck V, Moniruzzaman M, et al. Open Heart 2016;3:e000438.
  11. Badan Penelitian dan Pengembangan KEsehatan-Kementerian KEsehatan Republik Indonesia. Riset Kesehatan Dasar (RISKESDAS) 2013. 2013 [cited 2015 Agustus]. Available from: http://www.depkes.go.id/resources/download/ general/Hasil%20Riskesdas%202013.pdf.
  12. Badan Penyelenggara Jaminan Sosial Kesehatan. Peraturan Badan Penyelenggara Jaminan Sosial Kesehatan no 1 tahun 2014. 2014 [cited 2015 Agustus]. Available from: https://www.google.com/search?source=hp&ei= qaNzW9PpJsj6-QbQva7wBQ&q=Peraturan+Badan+Penyelenggara+Jaminan+ Sosial+Kesehatan+Nomor+1+Tahun+2014+tentang+Penyelenggaraan+Jaminan+Kesehtan&oq=Peraturan+Badan+Penyelenggara+Jaminan+Sosial+Kesehatan+Nomor+1+Tahun+2014+tentang+Penyelenggaraan+Jaminan+Kesehtan&gs_l=psy-ab.3...4401.4401.0.4711.2.1.0.0.0.0.0.0..0.0....0...1c.1.64.psy-ab..2.0.0.0 ...0.F_OdK9_fXKA
  13. Menteri Kesehatan Republik Indonesia. Pelaksanaan pelayanan kesehatan bagi peserta BPJS kesehatan pada fasilitas kesehatan tingkat pertama dan fasilitas kesehatan tingkat lanjutan dalam penyelenggaraan program jaminan kesehatan. 2014 [cited 2015 Agustus]. Available from: http://www.jkn.kemkes.go.id/ attachment/unduhan/SE%20ttg%20Pelaksanaan%20Pelayanan%20Kesehatan%20Bagi%20Peserta%20BPJS%20Kesehatan.pdf.
  14. Badan Penyelenggara Jaminan Sosial Kesehatan. Panduan praktis program rujuk balik bagi peserta JKN. [cited 2015 Agustus]. Available from: https://bpjs-kesehatan.go.id/bpjs/dmdocuments/4238e7d5f66ccef4ccd89883c46fcebc.pdf.
  15. Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12(4):263-77.
  16. Win TS, Chaiyakunapruk N, Suwankesawong W, Dilokthornsakul P, Nathisuwan S. Renin angiotensin system blockers-associated angioedema in the Thai population: analysis from Thai National Pharmacovigilance Database. Asian Pac J Allergy Immunol. 2015;33(3):227-35.
  17. Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012;(4):CD003040.
  18. Gillette M, Morneau K, Hoang V, Virani S, Jneid H. Antiplatelet management for coronary heart disease: advances and challenges. Curr Atheroscler Rep. 2016;18:35.
  19. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016;11(8):e0160046.
  20. Tran-Duy A, Vanmolkot FH, Joore MA, Hoes AW, Stehouwer CD. Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis. Int J Clin Pract. 2015;69(10):1088-111.
  21. Lim SY. Role of statins in coronary artery disease. Chonnam Med J. 2013;49(1): 1–6.
  22. Szyguła-Jurkiewicz B, Szczurek W, Król B, Zembala M. The role of statins in chronic heart failure. Kardiochir Torakochirurgia Pol. 2014;11(3):301–305.
  23. Van der Harst, de Boer RA. Statins in the treatment of heart failure. Circ Heart Fail. 2010;3:462-464.
  24. Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc. 2012;87(6):555–560.
  25. Kuwabara M, Kondo F, Hamada T, Takahashi JI, Takenaka N, Furuno T. Impact of statins therapy for ischemic heart disease patients with low-density lipoprotein cholesterol levels less than 100 mg/dL. Acta Cardiol Sin. 2016;32(5):565–569.
  26. Schlatter RP, Hirakata VN, Polancyk A. Estimating the direct costs of ischemic heart disease: evidence from a teaching hospital in Brazil, a retrospective cohort study. BMC Cardiovasc Disord. 2017;17:180.
  27. Ogah OS, Stewart S. Onwujekwe OE, Falase AO, Adebayo SO, Olunuga T, et al. Economic burden of heart failure: investigating outpatient and inpatient costs in Abeokuta, Southwest Nigeria. PLoS One. 2014;9(11):e113032.
  28. Schumock GT, Stubbings J, Wiest MD, Li EC, Suda KJ, Matusiak LM, et al. National trends in prescription drug expenditures and projections for 2018. Am J Health Syst Pharm. 2018;75(14):1023-1038.
  29. Patented Medicine Proces Review Board. The drivers of prescription drug expenditures – a methodological report. 2013 [cited 2018 Agustus 1]. Available from: http://www.pmprb-cepmb.gc.ca/CMFiles/NPDUIS/NPDUIS_Drivers_ Prescription_Drug_Expenditures_2013-12-13_EN.pdf.
  30. Lee IH, Bloor K, Hewitt C, Maynard A. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review. J Health Serv Res Policy. 2015;20(1):52-9.
  31. Insull W Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 Suppl):S3-S14.




DOI: https://doi.org/10.22146/jmpf.38170

Article Metrics

Abstract views : 4103 | views : 2981

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats